JPWO2021209897A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021209897A5 JPWO2021209897A5 JP2022562250A JP2022562250A JPWO2021209897A5 JP WO2021209897 A5 JPWO2021209897 A5 JP WO2021209897A5 JP 2022562250 A JP2022562250 A JP 2022562250A JP 2022562250 A JP2022562250 A JP 2022562250A JP WO2021209897 A5 JPWO2021209897 A5 JP WO2021209897A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- polynucleotide encoding
- seq
- vector
- psma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 186
- 102000040430 polynucleotide Human genes 0.000 claims description 186
- 239000002157 polynucleotide Substances 0.000 claims description 186
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 48
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 48
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 32
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
- 229960005486 vaccine Drugs 0.000 claims description 31
- 241000701161 unidentified adenovirus Species 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 16
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 14
- 208000007089 vaccinia Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 241000205701 Human adenovirus 26 Species 0.000 claims description 6
- 230000037452 priming Effects 0.000 claims description 6
- 241000598171 Human adenovirus sp. Species 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 238000009167 androgen deprivation therapy Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 3
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008848P | 2020-04-13 | 2020-04-13 | |
| US63/008,848 | 2020-04-13 | ||
| US202163158601P | 2021-03-09 | 2021-03-09 | |
| US63/158,601 | 2021-03-09 | ||
| PCT/IB2021/053041 WO2021209897A1 (en) | 2020-04-13 | 2021-04-13 | Psma and steap1 vaccines and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521194A JP2023521194A (ja) | 2023-05-23 |
| JP2023521194A5 JP2023521194A5 (https=) | 2024-04-05 |
| JPWO2021209897A5 true JPWO2021209897A5 (https=) | 2024-04-05 |
Family
ID=75562795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562250A Pending JP2023521194A (ja) | 2020-04-13 | 2021-04-13 | Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210315986A1 (https=) |
| EP (1) | EP4135757A1 (https=) |
| JP (1) | JP2023521194A (https=) |
| WO (1) | WO2021209897A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4448001A4 (en) * | 2021-12-16 | 2025-12-03 | Janssen Biotech Inc | PROSTATE CANCER VACCINES AND THEIR USES |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| FR2737222B1 (fr) | 1995-07-24 | 1997-10-17 | Transgene Sa | Nouveaux vecteurs viraux et lignee pour la therapie genique |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| EP0944717A1 (fr) | 1996-07-01 | 1999-09-29 | Aventis Pharma S.A. | Procede de production d'adenovirus recombinants |
| ATE477320T1 (de) | 1996-12-13 | 2010-08-15 | Schering Corp | Methoden zur virus-reinigung |
| CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US6440442B1 (en) | 1998-06-29 | 2002-08-27 | Hydromer, Inc. | Hydrophilic polymer blends used for dry cow therapy |
| EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| ATE519855T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus des serotyps ad11 |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US7714119B2 (en) * | 2004-07-13 | 2010-05-11 | Biosante Pharmaceuticals, Inc. | AAV vector compositions and methods for enhanced expression of immunoglobulins using the same |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| NZ601827A (en) * | 2007-10-18 | 2014-01-31 | Bavarian Nordic Inc | Use of mva to treat prostate cancer |
| EP2391638B1 (en) | 2009-02-02 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| CN102895659B (zh) * | 2011-07-29 | 2014-10-29 | 复旦大学 | 一种防治老年痴呆症复合疫苗及其制备方法 |
| DE102012108671A1 (de) | 2012-09-17 | 2014-05-28 | Paul Vahle Gmbh & Co. Kg | Metall-Fremdkörper-Erkennungssystem für induktive Energieübertragungssysteme |
| WO2015024664A1 (en) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating prostate cancer |
| EP3060232B1 (en) | 2013-10-23 | 2018-07-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| HUE040440T2 (hu) | 2014-11-04 | 2019-03-28 | Janssen Vaccines & Prevention Bv | Terápiás HPV16-oltóanyagok |
| KR20180042295A (ko) | 2015-08-20 | 2018-04-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 치료용 hpv18 백신 |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| CA3026342A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| KR102307065B1 (ko) | 2016-06-20 | 2021-09-30 | 얀센 백신스 앤드 프리벤션 비.브이. | 강력하고 균형 잡힌 양방향성 프로모터 |
| CA3035759A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| KR102718353B1 (ko) | 2016-10-17 | 2024-10-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| CN110268061B (zh) * | 2017-02-09 | 2024-07-16 | 扬森疫苗与预防公司 | 用于表达异源基因的有效的短启动子 |
| DK3649237T3 (da) | 2017-07-05 | 2022-02-21 | Nouscom Ag | Nukleinsyre- og aminosyresekvenser fra ikke-humant menneskeabe-adenovirus, vektorer indeholdende samme og anvendelser deraf |
| CA3078692A1 (en) * | 2017-11-03 | 2019-05-09 | Nouscom Ag | Vaccine t cell enhancer |
-
2021
- 2021-04-13 EP EP21719734.2A patent/EP4135757A1/en not_active Withdrawn
- 2021-04-13 US US17/228,871 patent/US20210315986A1/en not_active Abandoned
- 2021-04-13 JP JP2022562250A patent/JP2023521194A/ja active Pending
- 2021-04-13 WO PCT/IB2021/053041 patent/WO2021209897A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grosenbach et al. | Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects | |
| Hodge et al. | Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses | |
| Madan et al. | PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma | |
| JP2024105526A5 (https=) | ||
| JP2011500718A5 (https=) | ||
| Mennuni et al. | Efficient induction of T‐cell responses to carcinoembryonic antigen by a heterologous prime‐boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA | |
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| JP2022130623A5 (https=) | ||
| US20210369824A1 (en) | Methods and materials for treating cancer | |
| JP2021528367A5 (https=) | ||
| CA2527640A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| Harrop et al. | Viral vectors for cancer immunotherapy | |
| JPWO2021209897A5 (https=) | ||
| Song et al. | The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy | |
| Izzi et al. | Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains | |
| JPWO2020144615A5 (https=) | ||
| Shalev et al. | Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene | |
| RU2013113639A (ru) | Иммунотерапевтический способ лечения рака простаты | |
| US20220152168A1 (en) | Sequential heterologous boost oncolytic viral immunotherapy | |
| Naitoh et al. | Gene therapy—the future is here: a guide to the practicing urologist | |
| Hörig et al. | Prostate-specific antigen vaccines for prostate cancer | |
| JPWO2019219851A5 (https=) | ||
| US20110104101A1 (en) | Immunotherapy for Unresectable Pancreatic Cancer | |
| Hillman et al. | Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma | |
| Chen et al. | Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models |